William L. Redmond, PhD is a Member (Full Professor) and Director of the Immune Monitoring Laboratory at the Earle A. Chiles Research Institute (EACRI) at the Providence Cancer Institute. Dr. Redmond’s research seeks to elucidate the mechanisms by which various therapies including immune checkpoint blockade, T cell agonists, and common gamma chain cytokines (e.g., IL-2) can synergize with novel therapies to augment anti-tumor immunity. Furthermore, he seeks to identify biomarkers of response to treatment that may provide insight into the mechanisms by which immunotherapy improve outcomes in patients with advanced malignancies. Dr. Redmond has extensive experience with murine tumor models and, as Director, EACRI Immune Monitoring Laboratory, oversees translational research efforts seeking to develop and implement state-of-the-art immune profiling assays for the evaluation of anti-tumor immunity in cancer patients. This includes analysis of peripheral blood, serum, and tumor tissue by multi-parameter flow cytometry, multiplex immunohistochemistry, and next-gen sequencing including single-cell RNA-seq. Dr. Redmond expertise in tumor immunology has led to numerous peer-reviewed publications and grant support from agencies including the NIH/NCI, Susan G. Komen, Prostate Cancer Foundation, American Cancer Society, and V Foundation.